M. Vijay Reddy, Ph.D., Merck & Co., Inc. - Qepler Summits And Conferences

M. Vijay Reddy, Ph.D.

Sr. Principle Scientist
Merck & Co., Inc.
USA
For more than a century, Merck has been inventing medicines and vaccines for many of the world's most challenging diseases. We have always been and always will be inventing, and we do it for the single greatest purpose: Life.

Dr. M. Vijay Reddy is a Senior Principal Scientist in the department of Genetic Toxicology at Merck & Co., Inc., West Point, PA.

Vijay supports QSAR (Quantitative structure-activity relationships) related activities involving derisking molecules for potential genotoxicity.

Dr. Reddy received his Ph.D. in Biochemistry from Indian Institute of Science, Bangalore, with work involving production of antibodies to nucleic acids.

He joined Baylor College of Medicine as the Postdoc in Dr. Kurt Randerath’s lab and was one of the original developers of the famous 32P-postlabeling method for detection of DNA adducts, which was widely used and later featured with their photos on the coverage of Cancer Research journal for their original contribution.

He then worked at Mobil Oil Corporation and Covance Labs prior to joining Merck. He was a former GTA president, and has 56 publications and 42 meeting abstracts to his credit.

Related Sessions:

Genotoxic Impurities in
Pharmaceuticals Summit 2019

GTI strategies & new methodologies: analysis, in silico & regulations. Challenges & opportunities.
  • 11 Apr 2019
  • Berlin, DE
  • Pharma
Day 2: Friday, 12 April 2019
CASE STUDY: Assessment and control of potential mutagenic impurities to comply with ICH M7.
  • Various in silico (Q)SAR tools for evaluation
  • Lessons learnt when using more than one system
  • Use of structural analogs – Case study
  • Correlation between QSAR and Ames mutagenicity results – Case studies
View Details